Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease.
暂无分享,去创建一个
Ravy K. Vajravelu | J. Lewis | R. Mamtani | M. Gerich | B. Fennimore | A. Hans | F. Scott
[1] F. Johnson,et al. Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. , 2019, Journal of Crohn's & colitis.
[3] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.
[4] S. Targan,et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. , 2019, The New England journal of medicine.
[5] Frank I. Scott,et al. Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[6] B. Behm,et al. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.
[7] M. Murad,et al. Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease , 2018, Alimentary pharmacology & therapeutics.
[8] M. Regueiro,et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults , 2018, The American Journal of Gastroenterology.
[9] Frank I. Scott,et al. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. , 2018, Inflammatory bowel diseases.
[10] Z. Zeng,et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease , 2017, Journal of Gastroenterology.
[11] Frank I. Scott,et al. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] A. Bitton,et al. DOP074 Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis , 2014 .
[13] J. Lewis,et al. Impact of JC Virus Antibody Testing in Patients with Crohn's Disease with Loss of Response to Infliximab: A Markov Model , 2013, Inflammatory bowel diseases.
[14] P. Rutgeerts,et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.
[15] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[16] L. Peyrin-Biroulet,et al. Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review , 2013, Inflammatory bowel diseases.
[17] B. Strober,et al. Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up , 2013, The British journal of dermatology.
[18] G. Greenberg,et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.
[19] M. Turner,et al. Safety of Infliximab and Other Crohn's Disease Therapies: Treat™ Registry Data With a Mean of 5 Years of Follow-up , 2011 .
[20] K. Simon,et al. Anti‐JC virus antibodies: Implications for PML Risk Stratification , 2010, Annals of neurology.
[21] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[22] Thomas R Ten Have,et al. Determinants of the optimal first‐line therapy for follicular lymphoma: A decision analysis , 2010, American journal of hematology.
[23] L. Peyrin-Biroulet,et al. The Natural History of Adult Crohn's Disease in Population-Based Cohorts , 2010, The American Journal of Gastroenterology.
[24] F. Carrat,et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.
[25] M. Weinstein,et al. QALYs: the basics. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] K. Van Steen,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.
[27] P. Rutgeerts,et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.
[28] D. Margolis,et al. Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.
[29] Murray Krahn,et al. The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[30] P. Rutgeerts,et al. JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? , 2008, Gut.
[31] S. Schreiber,et al. Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.
[32] P. Rutgeerts,et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.
[33] S. Targan,et al. Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.
[34] J. Berger,et al. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. , 2005, The New England journal of medicine.
[35] P. Rutgeerts,et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.
[36] J. Rubenstein,et al. Infliximab Decreases Resource Use Among Patients With Crohn's Disease , 2002, Journal of clinical gastroenterology.
[37] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[38] J. Schwartz,et al. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. , 2000, Gastroenterology.
[39] B. Feagan,et al. An Evaluation of Utility Measurement in Crohn's Disease , 1997, Inflammatory bowel diseases.
[40] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[41] P. Rutgeerts,et al. IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. , 2019, Journal of Crohn's & colitis.
[42] B. Sands,et al. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.
[43] P. Rutgeerts,et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.
[44] A. Tosteson,et al. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[45] G. D'Haens,et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .
[46] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[47] R. N. Anderson,et al. National Vital Statistics Reports , 1999 .